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Presentation of Case
An eight-year-old boy from Togo pre-
sented with a nodule of 30 mm in diameter
at the left costal arch (Figure 1) clinically
compatible with Buruli ulcer disease (BUD)
at the ‘‘Centre Hospitalier Re´gional Mar-
itime’’ (CHR Maritime), Tse´vie´, in July
2010. His hometown, a village located close
to the river ‘‘Haho’’ in the central district
‘‘Yoto’’ of the ‘‘Re´gion Maritime’’, consti-
tutes one of the BUD-endemic foci in Togo
[1]. The patient’s BCG vaccination status
was positive and no other family member
was diagnosed with BUD before. The
lesion was laboratory confirmed by con-
ventional IS2404 PCR from a 3-mm punch
biopsy sample (Table 1) at the Department
of Infectious Diseases and Tropical Medi-
cine (DITM), Munich, and a full course of
rifampicin (300 mg/d) and streptomycin
(0.5 g/d) was administered for eight weeks
at the peripheral health post (‘‘Unite´ de
Soins Pe´riphe´rique’’, USP). The patient
was fully compliant throughout the entire
period of treatment and no complications
were reported. In September 2010, the
lesion was completely healed under scarifi-
cation (Figure 2) and the patient was
considered cured. Weekly follow-up was
conducted by the BUD nurse of the village
for three months following healing accom-
panied by monthly follow-up by the BUD
nurse of CHR Maritime. No pathological
findings were observed until June 2011. In
July 2011, the boy (in the meantime nine-
year-old) presented again with a secondary
nodule (diameter: 30 mm) at the back of
the right thigh (Figure 3) at CHRMaritime
one week after its emergence. The lesion
was clinically compatible with BUD and
clinical samples were collected and for-
warded to the newly established BUD
Reference Laboratory at the ‘‘Institut
National d’Hygie`ne’’ (INH), Lome´, as well
as DITM (Table 1). Microscopy of a Ziehl-
Neelsen stained FNA smear was (scanty)
positive and the presence of Mycobacterium
ulcerans DNA was confirmed by IS2404
real-time qPCR at DITM while conven-
tional IS2404 PCR remained negative for
all samples tested. The secondary lesion
ulcerated three weeks after emergence and
further samples were collected from the
ulcer (diameter: 25630 mm) and forward-
ed to DITM for analysis. Whereas IS2404
qPCR reconfirmed the presence of M.
ulcerans DNA, viability testing of M. ulcerans
by analysis of mycobacterial ribosomal 16S
RNA through a newly established 16S
rRNA RT qPCR (specificity: 100%, posi-
tivity rate for pre-treatment swab samples:
83.3% [95%-CI: 66.1%–100%], limit of
detection: six copies of the target sequence)
(unpublished data) and culture were nega-
tive (Table 1). Under stringent clinical
observation, conventional wound care by
daily cleaning with normal saline, disinfec-
tion with povidone-iodine, and sterile
dressing of the ulcerated lesion was per-
formed at the USP for two weeks. The
lesion healed completely (Figure 4) five
weeks after onset of disease. The patient’s
parents gave written informed consent for
publication.
Case Discussion
BUD caused by infection with M.
ulcerans may lead to extensive destruction
of the skin, soft tissue, and bone with
severe fibrous scarring and formation of
contractures if left untreated. Pathogenesis
of BUD is mediated by the cytotoxic and
immunosuppressive exotoxin mycolactone
[2]. During the last decade, significant
advances in the treatment of BUD have
been made and the introduction of
standardized antimycobacterial chemo-
therapy with rifampicin and streptomycin
resulted in recurrence rates below 2% [3].
While recurrences after surgical excision
alone presumably are attributable to the
persistence of mycobacteria in macroscop-
ically healthy tissue bordering surgical
excision [4], little is known about the
pathogenesis and immunological mecha-
nisms of secondary BUD lesions evolving
after completion of standardized antimy-
cobacterial treatment [5].
Development of new skin lesions during
antimycobacterial treatment are currently
assumed to be caused by immune-mediat-
ed, paradoxical reactions (i.e., deteriorat-
ing responses to treatment of an infection
after initial improvement) which are likely
Citation: Beissner M, Piten E, Maman I, Symank D, Jansson M, et al. (2012) Spontaneous Clearance of a
Secondary Buruli Ulcer Lesion Emerging Ten Months after Completion of Chemotherapy—A Case Report from
Togo. PLoS Negl Trop Dis 6(7): e1747. doi:10.1371/journal.pntd.0001747
Editor: Richard O. Phillips, Kwame Nkrumah University of Science and Technology (KNUST) School of Medical
Sciences, Ghana
Published July 31, 2012
Copyright:  2012 Beissner et al. This is an open-access article distributed under the terms of the Creative
Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
Funding: The research leading to these results has received funding from the European Community’s Seventh
Framework Programme (FP7/2007-2013) under grant agreement Nu 241500. The funders had no role in study
design, data collection and analysis, decision to publish, or preparation of the manuscript. The funder’s website
is accessible via http://ec.europa.eu/research/health/infectious-diseases/neglected-diseases/projects/012_en.
html.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: beissner@lrz.uni-muenchen.de
www.plosntds.org 1 July 2012 | Volume 6 | Issue 7 | e1747
to be triggered by mycobacterial antigens
and immune-stimulators released from
killed mycobacteria [6,7].
Ruf et al. recently reported two BUD
patients from Benin who developed a
series of secondary BUD lesions after
completion of chemotherapy [5]. These
lesions may partly represent secondary
infection foci that were already present
during treatment and appeared as a
consequence of delayed paradoxical reac-
tions. However, in particular, lesions
occurring more than one year after
completion of treatment may have been
associated with new M. ulcerans infection or
mycobacteria surviving antimycobacterial
treatment and may have been resolved by
immune responses triggered by successful
treatment of primary lesions.
In accordance with the other cases
published so far, in the present case a
secondary M. ulcerans lesion was laboratory
confirmed by microscopic detection of
acid fast bacilli and IS2404 real-time
qPCR, whereas cultures remained nega-
tive. Furthermore, analysis of mycobacte-
rial ribosomal 16S RNA did not provide
evidence for the presence of viable bacilli.
As shown by Ruf et al. histopathological
analysis of surgically excised late-onset
secondary lesions revealed characteristical
features of BUD as well as massive
leukocyte infiltration of necrotic areas
characteristic for successfully treated le-
sions. As there was no surgical intervention
for the secondary lesion of the Togolese
patient, clinical samples for histopatholog-
ical analysis were not available.
Pathogenesis of the secondary BUD
lesion in the present case might either be
attributable to a second unrecognized
focus of killed M. ulcerans during antibiotic
chemotherapy ten months earlier which
became clinically apparent due to a late
inflammatory response to residual myco-
bacterial antigens (i.e., late paradoxical
reaction), or to re-inoculation of M. ulcerans
that was cleared by an elevated immune
response primed by the successful initial
treatment. However, available laboratory
methods did not allow distinguishing
between late paradoxical reaction and
spontaneous host clearance during a
second exposure.
While mycolactone plays a major role in
the pathogenesis of primary BUD lesions,
the question whether and to which extent
the toxin is involved in the pathogenesis of
secondary BUD lesions remains unre-
solved. Sarfo et al. recently demonstrated
the detection of mycolactone in human
tissue, suggesting its usefulness as a
biomarker for monitoring the clinical
response to treatment [8]. Detection of
mycolactone in secondary lesions may
support the hypothesis that new infection
foci are associated with secondary lesions.
However, to our knowledge, data on
mycolactone in secondary lesions are still
lacking.
Beside previous anecdotal observations
on spontaneous clearance of lesions in
Figure 1. Primary nodule at the left costal arch, June 2010.
doi:10.1371/journal.pntd.0001747.g001
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clinically suspected BUD cases, Gordon
et al. recently reported the first case of
spontaneous resolution of a laboratory
confirmed BUD ulcer in a patient from
Australia [9]. Whereas the secondary
lesions of the two BUD patients from
Benin were surgically excised, the ulcerat-
ed lesion of the Togolese case also healed
under conventional wound care.
In the absence of evidence-based guide-
lines for reliable identification of late-onset
secondary immune-mediated lesions and
Figure 2. Scar of the primary nodule at the left costal arch, September 2010.
doi:10.1371/journal.pntd.0001747.g002
Learning Points
N Secondary BUD lesions may occur as paradoxical reaction (i.e., deteriorating
responses to treatment of an infection after initial improvement) during or
shortly after treatment; late-onset secondary lesions may occur up to more than
one year after completion of treatment.
N Characteristic diagnostic results for secondary BUD lesions are positive
microscopy and PCR results without evidence for viable bacilli.
N The case of the Togolese patient shows that complete healing of secondary
lesions without antibiotic or surgical treatment occurs. Therefore, conventional
wound care can be considered as a treatment option if continuous clinical
observation is possible.
www.plosntds.org 4 July 2012 | Volume 6 | Issue 7 | e1747
Figure 3. Secondary ulcerated nodule at the back of the right thigh, July 2011.
doi:10.1371/journal.pntd.0001747.g003
www.plosntds.org 5 July 2012 | Volume 6 | Issue 7 | e1747
their clinical management, it may be
advisable to consider the possibility of
spontaneous healing under stringent clin-
ical observation and regular wound care.
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